Fig. 6

DCZ5417 in combination with melphalan or lenalidomide functions synergistically to exert cytotoxicity. a H929 and OCI-MY5 cells were treated with DCZ5417 (5–40 µmol/L) plus melphalan (1.25–10 µmol/L) for 48 h, which was followed by a CCK-8 assay to determine cell viability. The synergistic cytotoxic effects of DCZ5417 and melphalan are shown. CI < 1 indicated synergistic activity, as determined using CalcuSyn software. The Fa fraction represented the cells affected. b H929 and OCI-MY5 cells were treated with DCZ5417 (5–20 µmol/L) plus lenalidomide (1.25–5 nmol/L) for 48 h, which was followed by a CCK-8 assay to determine cell viability. c Purified CD138⁺ patient MM cells were inoculated in 96-well plates and treated with DCZ5417 and melphalan for 48 h. CCK-8 assay was performed to assess viability. d Purified CD138⁺ patient MM cells were inoculated in 96-well plates and treated with DCZ5417 and lenalidomide for 48 h. CCK-8 assay was performed to assess viability. Isobologram analysis shows the synergistic cytotoxic effect. Data are presented as the means ± SD of 3 independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus the control group